Merrimack Pharmaceuticals Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Mizuho Securities Reiterates Bullish Stance on Merrimack Pharmaceuticals (MACK) Into MM-398 PDUFA Date
August 11, 2015 7:46 AM EDTMizuho Securities analyst Peter Lawson reiterated an Outperform rating and $16 price target on Merrimack Pharmaceuticals (NASDAQ: MACK) heading into an October 24 PDUFA date for MM-398.
"The company remains one of our favorite biotech plays and we feel it is overlooked by investors, given... More
Merrimack Pharma (MACK) Tops Q2 EPS by 10c
August 10, 2015 5:06 PM EDTMerrimack Pharma (NASDAQ: MACK) reported Q2 EPS of ($0.21), $0.10 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $36.6 million versus the consensus estimate of $17.57 million.
For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.
... More